RT Journal Article SR Electronic T1 SEVERE ASTHMA – ADDING NEW EVIDENCES. Latin American Thoracic Society-ALAT JF ERJ Open Research JO erjor FD European Respiratory Society SP 00318-2020 DO 10.1183/23120541.00318-2020 A1 G García A1 M Bergna A1 JC Vásquez A1 MC Cano Salas A1 JL Miguel A1 C Celis Preciado A1 A Acuña Izcaray A1 M Barros Monge A1 N García Batista A1 I Zabert A1 JL Mayorga A1 R Casanova Mendoza A1 M Gutierrez A1 MF Montero Arias A1 L Urtecho Perez A1 M Antúnez A1 V Williams Derby A1 A Villatoro Azméquita A1 L Motiño A1 A De Oliveira A1 D Rey Sanchez A1 M Arroyo A1 M. Rodriguez YR 2020 UL http://openres.ersjournals.com/content/early/2020/10/01/23120541.00318-2020.abstract AB This document constitutes a summary of the Clinical Practice Guidelines (CPGs) prepared at the initiative of the Latin American Thoracic Society (ALAT). Due to new evidence in the treatment of severe asthma, it was agreed to select 6 clinical questions, and the corresponding recommendations are provided herein. After considering the quality of the evidence, the balance between desirable and undesirable impacts and the feasibility and acceptance of procedures, the following recommendations were established: 1) We do not recommend the use of an ICS plus formoterol as rescue medication in the treatment of severe asthma. 2) We suggest performing many more high-quality randomised studies to evaluate the efficacy and safety of tiotropium in patients with severe asthma. 3) Omalizumab is recommended in patients with severe uncontrolled allergic asthma with serum IgE levels above 30 IU. 4) Anti-IL-5 drugs are recommended in patients with severe uncontrolled eosinophilic asthma (cut-off values above 150 cells·µL−1 for mepolizumab and above 400 cells·µL−1 for reslizumab). 5) Benralizumab is recommended in adult patients with severe uncontrolled eosinophilic asthma (cut-off values above 300 cells·µL−1). 6) Dupilumab is recommended in adult patients with severe uncontrolled allergic and eosinophilic asthma and in adult patients with severe corticosteroid-dependent asthma.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. García reports and GRANTS RESEARCH : Novartis, GSK, Boehringer Ingelheim, Astra Zeneca, Sanofi.CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis;SanofiConflict of interest: Dr. Bergna reports and GRANTS RESEARCH : Novartis, GSK, Boehringer Ingelheim, Roche, Astra Zeneca, Sanofi. CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis.Conflict of interest: Dr. Vazquez reports CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis, Boehringer Ingelheim,Conflict of interest: Dr. Cano reports CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis, Boehringer Ingelheim,Conflict of interest: Dr. Acuña reports CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis, Boehringer Ingelheim,Conflict of interest: Dr. Cellis reports and GRANTS RESEARCH : Novartis, Astra Zeneca, Sanofi.CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis. SanofiConflict of interest: Dr. Acuña reports CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis, Boehringer Ingelheim,Conflict of interest: Dr. Barros reports and GRANTS RESEARCH : Novartis, GSK, Boehringer Ingelheim, Astra Zeneca.CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis.Conflict of interest: Dra Garcia reports CONSULTANT / ADVISOR / SPEAKER: Astra Zeneca, NovartisConflict of interest: Dr. MAYORGA-BUTRON has nothing to disclose.Conflict of interest: Dr Casanova has nothing to disclose.Conflict of interest: Dra Gutierrez has nothing to disclose.Conflict of interest: Dra Montero reports GRANTS RESEARCH : NovartisConflict of interest: Dra Utrecho Perez has nothing to disclose.Conflict of interest: Dr. Antunez reports CONSULTANT / ADVISOR / SPEAKER: GSK, Astra Zeneca, Novartis, Boehringer Ingelheim,Conflict of interest: Dra Williams has nothing to disclose.Conflict of interest: Dr. Villatoro has nothing to disclose.Conflict of interest: Dr. Motiño has nothing to disclose.MotiñoConflict of interest: Dra. De Oliveira has nothing to disclose.Conflict of interest: Dra Rey Sanchez has nothing to disclose.Conflict of interest: Dra Arroyo has nothing to disclose.Conflict of interest: Sr Rodriguez has nothing to disclose.